Today
+0.25%
5 Days
+1.25%
1 Month
+1.27%
6 Months
-13.10%
Year to Date
-4.09%
1 Year
+11.27%
• Cencora stock fell as non-prime Walgreens pharmaceutical volume moved to competitors. • Investors focused on revenue risks despite reiterated full-year earnings per share guidance. • Cencora reported $321.33B in annual revenue, ranking first in its industry.
• Stifel reiterated a Buy rating with a $90.00 price target on Boston Scientific. • Analysts maintain positive ratings with price targets ranging from $92 to $120. • Acquisition of Penumbra for $14.5 billion is expected to boost cardiovascular portfolio.


| Shareholders | Proportion |
|---|---|
| BlackRock Institutional Trust Company, N.A. | 6.60% |
| State Street Investment Management (US) | 4.78% |
| Walgreens Holding Co | 3.84% |
| T. Rowe Price Investment Management, Inc. | 3.44% |
| Shareholder Types | Proportion |
|---|---|
| Investment Advisor | 45.00% |
| Investment Advisor/Hedge Fund | 28.30% |
| Corporation | 3.84% |
| Research Firm | 3.04% |
Related Instruments
Popular Instruments